How to Identify Pharma BD Opportunities

What Is a BD Opportunity Analysis?

A BD opportunity analysis evaluates a company's pipeline, deal precedents, financial signals, and recent activity to identify potential partnering opportunities. Ask a business-development analyst to run one overnight, and they'll usually tell you the writing was never the bottleneck, the two days before it were.

Patsnap Open calls the structured output of that analysis a BD Opportunity Scan, this guide's term for a pharma partnering-opportunity report: a shortlist with its receipts attached, naming which assets, at what stage, backed by what deal precedent, and read against financial reports and recent news. Whether you call this a BD opportunity assessment, a partnering opportunity analysis, or a licensing-target screen, the underlying evidence chain is the same. This guide walks through building one with Patsnap Open. No prior MCP experience required, by the end, you'll have connected two MCP servers and produced a shortlist you can hand straight to a deal team, with every claim in it traced back to a record.

What Data Do You Need for BD Opportunity Analysis?

The traditional version of pharma business development research is familiar to anyone who's done biotech deal sourcing or competitive intelligence work. Open the target company's website. Pull whatever's in the latest investor deck. Search a deal-tracking database for precedent. Skim an annual report for a strategic hint. Check the trade press in case something moved this week. Each of those lives in a different kind of source, and none of them were built to talk to each other.

None of this is hard, exactly, it's just slow, and the slowness compounds. A deal count isn't a quality signal by itself: a crowded target might mean real competition, or it might mean the terms are already well understood. An upfront payment, a milestone ceiling, and a total deal value are three different numbers, and reading them as one inflates or deflates a shortlist's credibility. And a single attractive asset can hide a bigger opportunity behind it, or turn out to be the company's only one, you can't tell which without checking the rest of the pipeline.

How MCP Servers Automate BD Research

This is exactly the kind of work AI agents have gotten good at, reading across scattered sources and holding the details straight, provided they can actually reach the data instead of guessing at it.

Patsnap Open exposes exactly this kind of tool over MCP, built on the same company, pipeline and deal records used across Patsnap's patent and life-science products. That matters here specifically: the agent isn't scraping a webpage or estimating a figure, it's reading a structured record with an identifier attached, which is what lets the final report cite its sources instead of asserting them.

How to Build a Pharma Partnering Shortlist with Patsnap Open

Here's the whole mechanism in one picture: your AI client talks MCP to two Patsnap Open servers, each exposing a handful of callable tools, and the tool results become the report.

Fig. 2, One AI client, two MCP servers, four tools, one report. Every arrow above is a real connection you'll make below.

Building it starts before the first tool call, connecting the two MCP servers. That takes five minutes:

1. Get a Patsnap Open API key. Sign up at the Patsnap Open Developer Portal, 10,000 free credits, no credit card required.
2. Open the MCP server pages. Visit Company & Deal Intelligence and Current Awareness on the marketplace, and generate a connection URL from each using your API key.
3. Add both URLs to an MCP-capable client. Paste them into your client's MCP/connector settings, Claude, ChatGPT, Cursor, or any client that supports remote MCP servers, and confirm the four tools below are visible.

Connect the following Patsnap Open MCP server(s) to this client:

Company & Deal Intelligence: https://connect.patsnap.com/1f8934/logic-mcp?apikey=YOUR_API_KEY
Current Awareness: https://connect.patsnap.com/401c6d/logic-mcp?apikey=YOUR_API_KEY

Replace YOUR_API_KEY with my Patsnap Open API key. After connecting, confirm that drug_deal_search and news_search are available. Do not begin the research workflow yet.

Once connected, four tools across those two servers cover the whole evidence chain:

Because the first three tools live on one server, one connection is enough to call all of them in the same conversation. From there, the four calls run in a fixed order:

1. Ask for drug_deal_search, the deal-search tool on Company & Deal Intelligence, for the target or therapeutic area, sorted by date, to see what deal-making already looks like there.
2. For every company that shows up as a licensor, licensee, or a notable non-partnered asset owner, call organization_pipeline_fetch, same server, to check whether their pipeline is one asset deep or a real platform.
3. Run financial_report_search, also on Company & Deal Intelligence, querying by company name and topic rather than a target abbreviation, that's the one query-design detail that decides whether the tool returns anything useful.
4. Close with news_search on the separate Current Awareness server, phrased in focused biology or drug terms rather than generic words like "news" or "deal." If nothing comes back, say so, a null result is evidence too.

Fill in the fields below, then paste the prompt into your connected AI client. The main request stays readable; the exact tool sequence is available as optional technical detail.

Using Patsnap Open's Company & Deal Intelligence and Current Awareness connections, prepare a BD Opportunity Scan for:

Target or therapeutic area: [TARGET / THERAPEUTIC AREA]
Geography: [GEOGRAPHY]
Decision: [BUSINESS DEVELOPMENT / PARTNERING / INVESTMENT]
Deal window: since [START DATE]

Review licensing, collaboration, acquisition, and option-deal precedents. Examine the pipelines of relevant licensors, licensees, and non-partnered asset owners, then add financial context and recent momentum where evidence is available.

Return an executive assessment, target or area landscape, deal precedents, financial and strategic signals, current momentum, a partnering shortlist, evidence gaps, and recommended next checks. Cite record identifiers, label directional counts, and never state a figure that was not retrieved.

Example: BD Opportunity Scan Report

Two real scans show this end to end. Model Medicines, Inc. came back with an RdRp- and BRD4-targeted infectious-disease pipeline, all Preclinical. Brise Pharma came back with a CGRP and neuralgia pipeline spanning Discovery through Phase 2, plus three comparable deal precedents. Same four tools, two shortlists that look nothing alike:

Fig. 3, The BD Opportunity Scan dashboard built from this data: stat tiles, the pipeline-stage chart, both companies' asset tables, and the deal-precedent table, comparing Model Medicines, Inc. and Brise Pharma.

The dashboard above compares two companies at a glance. Here's what the underlying report reads like when you open just one, an excerpt structured from the actual Brise Pharma evidence chain:

The report itself doesn't have to stop at plain text. Once the evidence is in the conversation, you can ask the same AI client to turn it into a Word document, a slide deck, or a formatted HTML page, and you can feed in your own supplementary material (an internal pipeline note, a prior diligence memo, a specific list of competitors to check) alongside the MCP results, so the output reflects both what Patsnap Open retrieved and what you already know.